Seen And Heard: Congressional Investigator Slams FDA Office Of Chief Counsel On Heparin Case
This article was originally published in PharmAsia News
Executive Summary
A senior investigator for the House Energy and Commerce Committee testified at an April 29 hearing that FDA's Office of Chief Counsel had thwarted a congressional investigation into heparin contamination in China. David Nelson said the OCC refused to provide documents relating to FDA's inspection process and would not let investigators interview OCC staff attorneys
You may also be interested in...
U.S. FDA’s Poor Performance ‘Invites Catastrophe’ – U.S. Congressional Committee On Heparin Investigation
The House Energy & Commerce Subcommittee on Oversight and Investigations simultaneously lauded and criticized U.S. FDA's handling of the heparin contaminant safety issue, which FDA now says was most likely the result of intentional actions
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).